Quantum Biopharma is preparing to seek permission in the U.S. to launch its planned clinical trial of Lucid-MS, an oral therapy that aims to slow myelin loss — which ultimately results in the neurological problems that drive multiple sclerosis (MS) — in people with the progressive disease. The company said it expects to submit an […]
The post Lucid-MS moves toward clinical trial in US that will enroll MS patients appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com